ArticleProstate cancer and prostatic diseases2020
GLUT1 expression in high-risk prostate cancer: correlation with
Article in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Prospective Intraindividual Comparison of Ga-68 PSMA and F-18 FDG Dual-Tracer PET/CT Imaging in Evaluation of High-Grade Prostate Cancer.World journal of nuclear medicine · 2026Article
- Biomimetic nanomodulator reprograms glycolysis-driven immunosuppressive microenvironment to potentiate photothermal immunotherapy in cold tumors.Materials today. Bio · 2026Article
- Cellular Origins and Context-Dependent Prognostic Effects of Lactate Metabolism Genes Reveal Novel Molecular Subtypes in Gastric Cancer.Current issues in molecular biology · 2026Article
- Dual-tracer PET/CT identifies an aggressive PSMA-negative/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer.Cell death & disease · 2025Article
- Perfluoro-JACS Au · 2025Article
- GLUT1 as a Potential Therapeutic Target in Glioblastoma.Brain sciences · 2025Review
- Relationship between MRI features and HIF-1α, GLUT1 and Ki-67 expression in pituitary adenoma with cystic degeneration.BMC medical imaging · 2025Article
- Targeting Glucose Transporter 1 (GLUT1) in Cancer: Molecular Mechanisms and Nanomedicine Applications.International journal of nanomedicine · 2025Review
- Head-to-head comparison ofFrontiers in oncology · 2025Article
- High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate.Prostate cancer and prostatic diseases · 2024Article
- Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer.Korean journal of radiology · 2024Article
- Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.Scientific reports · 2024Article
- Article
- Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance.International journal of molecular sciences · 2023Article
- The potential role of reprogrammed glucose metabolism: an emerging actionable codependent target in thyroid cancer.Journal of translational medicine · 2023Review
- Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?Cancers · 2023Review
- Clinical advancement of precision theranostics in prostate cancer.Frontiers in oncology · 2023Review
- Synthesis, radiolabeling, and evaluation of 68Ga-labeled aminoquinoxaline derivative as a potent PFKFB3-targeted PET tracer.Frontiers in chemistry · 2023Article
- Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour
methodsRetrospective analysis was conducted for 94 patients diagnosed with a Gleason sum ≥8 adenocarcinoma of the prostate at biopsy between July 2011 and July 2014 who underwent
resultsWith a median follow-up of 4.5 years, 56% (n = 53) of patients had biochemical recurrence (BCR), 7% (n = 7) progressed to castration-resistant prostate cancer (CRPC) disease, 13% (n = 12) developed metastasis and 6% (n = 6) died. Correlation was found between GLUT1 expression and SUVmax level (r = 0.25, p = 0.02). In addition, SUV
conclusionsGLUT1 expression in PCa tumours correlates with
Indexed as
Identifiers
31932660What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.